Physician profile
Frederick Joseph Pakron
NPI 1538196142
$7,179.23
in general payments reported to CMS, 2019-2025
35 companies · $1,682 in 2025
The $1,682 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,417 · 2020: $566 · 2021: $615 · 2022: $852 · 2023: $880 · 2024: $1,166 · 2025: $1,682.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,629 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,628.62 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,830.37 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,095.51 | 2019-2025 | Tezspire, Breztri |
| Mallinckrodt Hospital Products INC. | $714.39 | 2022-2025 | Acthar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $373.72 | 2019-2024 | Ofev, Stiolto Respimat |
| Actelion Pharmaceuticals US, INC. | $312.81 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Mylan Specialty L.P. | $311.02 | 2019-2024 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $259.02 | 2019-2025 | Dupixent |
| Grifols USA, LLC | $227.89 | 2019-2025 | Prolastin-C Liquid |
| Verona Pharma, INC. | $221.60 | 2025 | Ohtuvayre |
| Ani Pharmaceuticals, INC. | $187.79 | 2024-2025 | Purified Cortrophin Gel |
| Advanced Respiratory, INC | $180.29 | 2020 | |
| Genzyme Corporation | $161.67 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $156.33 | 2020-2025 | Glassia |
| United Therapeutics Corporation | $142.86 | 2023-2025 | Tyvaso, Tyvaso |
| Viatris Specialty LLC | $135.97 | 2025 | Yupelri |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $119.44 | 2023-2024 | Tezspire |
| Electromed, INC. | $94.16 | 2019-2025 | Smartvest |
| Genentech USA, INC. | $73.45 | 2021-2022 | |
| Mallinckrodt Enterprises LLC | $63.09 | 2019 | |
| Baxter Healthcare | $62.95 | 2024-2025 | Hillrom - Vest System Model 105 Home Care |
| Philips North America LLC | $62.91 | 2023-2025 | Vest Therapy Und |
| Insmed, INC. | $54.91 | 2025 | Arikayce |
| Merck Sharp & Dohme LLC | $53.30 | 2023 | Zerbaxa, Recarbrio, Dificid |
| Vifor Pharma, INC. | $46.91 | 2024 | Zemaira |
| Shire North American Group INC | $44.68 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $31.96 | 2022-2023 | |
| Circassia INC. | $29.94 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $18.75 | 2019 | |
| 3b Medical, INC. | $18.19 | 2025 | Luna |
| Novartis Pharmaceuticals Corporation | $17.37 | 2019 | |
| Itamar Medical INC | $17.10 | 2024 | Watchpatone |
| Apria Healthcare LLC | $15.94 | 2021 | |
| Lilly USA, LLC | $14.69 | 2025 | Zepbound |
| Paratek Pharmaceuticals, INC. | $14.59 | 2021 | |
| Axsome Therapeutics, INC. | $13.66 | 2025 | Sunosi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frederick Pakron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.